Recent Updates
Recently added Catalysts
STRO Positive Sentiment

ESMO Congress 2023 – Presentation

Key Takeaway: At the ESMO Congress 2023, Sutro Biopharma presented data on Luveltamab Tazevibulin (STRO-002), an antibody-drug conjugate targeting the folate receptor alpha. The results from the Phase 1 Dose Expansion study demonstrated clinical activity in patients with recurrent epithelial endometrial cancer, suggesting a potential new treatment option in this area.
Price reaction · baseline $31.9 (2023-10-20 close) · clean, no other STRO news in the window
day 0 close
-7.5%
day 1
-12.9%
day 3 · peak
-14.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Luveltamab Tazevibulin shows clinical activity in recurrent epithelial endometrial cancer.
  • The presentation at ESMO Congress 2023 highlights promising results.
  • The Phase 1 Dose Expansion study indicates potential for further development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
STRO-004
Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCC

Full Press Release Details

[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” categories=”off” comments=”off” admin_label=”ESMO Congress 2023 – Presentation” _builder_version=”4.17.1″ title_level=”h2″ title_text_color=”#0c71c3″ title_font_size=”28px” title_letter_spacing=”1px” title_line_height=”1.4em” meta_text_color=”#000000″ global_colors_info=”{}”][/et_pb_post_title][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.1″ _module_preset=”default” text_font_size=”19px” global_colors_info=”{}”]
Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2024/04/ESMO2023_STRO-002_mini-oral-presentation_FINAL_10222023.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Download ESMO Congress 2023 Presentation – Button” _builder_version=”4.23.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”15044,15045,15046,15047,15048,15049,15050,15051,15052″ fullwidth=”on” _builder_version=”4.23.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][/et_pb_column][/et_pb_row][/et_pb_section]

Frequently Asked Questions

What is Luveltamab Tazevibulin?

Luveltamab Tazevibulin (STRO-002) is an antibody-drug conjugate targeting the folate receptor alpha.

What were the results presented at ESMO 2023?

The presentation highlighted clinical activity of STRO-002 in recurrent epithelial endometrial cancer.

What phase is the STRO-002 study currently in?

The study is in the Phase 1 Dose Expansion stage.

Who presented the findings at ESMO Congress 2023?

Sutro Biopharma presented the findings during the congress.

Last updated: Oct 22, 2023